#GLP1 #Pharma #Strategy #MarketAccess #PharmaGambit To view or add a comment, sign in AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS VESALIUS-CV Subgroup Results Show Repatha Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk Diabetes New Real-World Data Highlight Treatment Gaps in Current Obesity and Diabetes Care THOUSAND OAKS, Calif., [...] #LosAngeles #OrangeCountyCA #Biotech #Lifescience #News To view or add a comment, sign in AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS VESALIUS-CV Subgroup Results Show Repatha Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk Diabetes New Real-World Data Highlight Treatment Gaps in Current Obesity and Diabetes Care THOUSAND OAKS, Calif., [...] To view or add a comment, sign in Imagine telling a pharmacist in 2015: A diabetes drug will soon be used for weight loss, heart protection, kidney disease, fatty liver disease, and even sleep apnea. Most people would have laughed

Physician Certification Requirements
no validated human data exist
The medication attained as much as a 75% decrease in liver fat, in addition to a 20% lower body mass
These drugs, Reid says, signal to the brain to lower appetite, which leads to significant changes in metabolism
Affordable Alternative: Compounding pharmacies often offer more affordable options compared to brand-name semaglutide, especially if youre managing diabetes over the long term